2 minutes

Rite Aid (RAD) 2Q17 RESULTS: ACQUISITION ON TRACK TO CLOSE IN 2H16

Primary Analyst: Coresight Research
Contributors
Primary Analyst: Coresight Research
Insight Report

Executive Summary

  • Rite Aid reported adjusted EPS of $0.03, beating the $0.02 consensus estimate and up from last year’s $0.02.
  • Businesses that contributed to the positive results included its EnvisionRX PBM, and its strong front-end segment. There was some improvement in prescription drug costs, which was offset by challenging reimbursement rates.
  • The company continues to believe that the announced acquisition of Rite Aid by Walgreens will close in the second half of 2016.
You are currently viewing a preview of this report.

Please select an access option to view the full report. Hide Options -

Get unlimited access to all our research with one of our subscription plans.

View Subscription Plans
or

Contact us to purchase this report.

Contact us